• 1
    Sewell KL, Trentham, DE. Pathogenesis of rheumatoid arthritis [review]. Lancet 1993;341: 2836.
  • 2
    Vaughan JH. Infection and rheumatic diseases: a review (2). Bull Rheum Dis 1990; 39: 18.
  • 3
    Saal JG, Krimmel M, Steidle M, Gerneth F, Wagner S, Fritz P, et al. Synovial Epstein-Barr virus infection increases the risk of rheumatoid arthritis in individuals with the shared HLA–DR4 epitope. Arthritis Rheum 1999; 42: 148596.
  • 4
    Takei M, Mitamura K, Fujiwara S, Horie T, Ryu J, Osaka S, et al. Detection of Epstein-Barr virus-encoded small RNA 1 and latent membrane protein 1 in synovial lining cells from rheumatoid arthritis patients. Int Immunol 1997; 9: 73943.
  • 5
    Zhang L, Nikkari S, Skurnik M, Ziegler T, Luukkainen R, Mottonen T, et al. Detection of herpesviruses by polymerase chain reaction in lymphocytes from patients with rheumatoid arthritis. Arthritis Rheum 1993; 36: 10806.
  • 6
    Harrison B, Silman A, Barrett E, Symmons D. Low frequency of recent parvovirus infection in a population-based cohort of patients with early inflammatory polyarthritis. Ann Rheum Dis 1998; 57: 3757.
  • 7
    Takahashi Y, Murai C, Shibata S, Munakata Y, Ishii T, Ishii K, et al. Human parvovirus B19 as a causative agent for rheumatoid arthritis. Proc Natl Acad Sci U S A 1998; 95: 822732.
  • 8
    Einsele H, Steidle M, Muller CA, Fritz P, Zacher J, Schmidt H, et al. Demonstration of cytomegalovirus (CMV) DNA and anti-CMV response in the synovial membrane and serum of patients with rheumatoid arthritis. J Rheumatol 1992; 19: 67781.
  • 9
    Tamm A, Ziegler T, Lautenschlager I, Nikkari S, Mottonen T, Luukkainen R, et al. Detection of cytomegalovirus DNA in cells from synovial fluid and peripheral blood of patients with early rheumatoid arthritis. J Rheumatol 1993; 20: 148993.
  • 10
    Takasawa N, Munakata Y, Ishii KK, Takahashi Y, Takahashi M, Fu Y, et al. Human parvovirus B19 transgenic mice become susceptible to polyarthritis. J Immunol 2004; 173: 467583.
  • 11
    Yarilin DA, Valiando J, Posnett DN. A mouse herpesvirus induces relapse of experimental autoimmune arthritis by infection of the inflammatory target tissue. J Immunol 2004; 173: 523846.
  • 12
    Zare F, Bokarewa M, Nenonen N, Bergstrom T, Alexopoulou L, Flavell RA, et al. Arthritogenic properties of double-stranded (viral) RNA. J Immunol 2004; 172: 565663.
  • 13
    Firestein GS, Zvaifler NJ. Immunopathogenesis of rheumatoid arthritis [review]. Immunol Ser 1991; 54: 14161.
  • 14
    Miossec P. Cytokines and the pathophysiology of bone erosions in rheumatoid arthritis [review]. Rev Rhum Engl Ed 1997; 64 Suppl 6:89S91S.
  • 15
    Thomas R. Antigen-presenting cells in rheumatoid arthritis [review]. Springer Semin Immunopathol 1998; 20: 5372.
  • 16
    Steinman RM, Nussenzweig MC. Inaugural article: avoiding horror autotoxicus: the importance of dendritic cells in peripheral T cell tolerance [review]. Proc Natl Acad Sci U S A 2002; 99: 3518.
  • 17
    Page G, Lebecque S, Miossec P. Anatomic localization of immature and mature dendritic cells in an ectopic lymphoid organ: correlation with selective chemokine expression in rheumatoid synovium. J Immunol 2002; 168: 533341.
  • 18
    Radstake TR, Blom A, Sloetjes A, van Gorselen EO, Pesman GJ, Engelen L, et al. Elevated FcGRII expression and aberrant TNF-α production by mature DC from patients with active rheumatoid arthritis (RA). Ann Rheum Dis 2004; 63: 155663.
  • 19
    Weyand CM, Goronzy JJ. Ectopic germinal center formation in rheumatoid synovitis [review]. Ann N Y Acad Sci 2003; 987: 1409.
  • 20
    Leung BP, Conacher M, Hunter D, McInnes IB, Liew FY, Brewer JM. A novel dendritic cell-induced model of erosive inflammatory arthritis: distinct roles for dendritic cells in T cell activation and induction of local inflammation. J Immunol 2002; 169: 70717.
  • 21
    Morita Y, Yang J, Gupta R, Shimizu K, Shelden EA, Endres J, et al. Dendritic cells genetically engineered to express IL-4 inhibit murine collagen-induced arthritis. J Clin Invest 2001; 107: 127584.
  • 22
    Kaisho T, Akira S. Regulation of dendritic cell function through Toll-like receptors [review]. Curr Mol Med 2003; 3: 37385.
  • 23
    Matzinger P. The danger model: a renewed sense of self. Science 2002; 296: 3015.
  • 24
    Vabulas RM, Ahmad-Nejad P, da Costa C, Miethke T, Kirschning CJ, Hacker H, et al. Endocytosed HSP60s use toll-like receptor 2 (TLR2) and TLR4 to activate the Toll/interleukin-1 receptor signaling pathway in innate immune cells. J Biol Chem 2001; 276: 313329.
  • 25
    Okamura Y, Watari M, Jerud ES, Young DW, Ishizaka ST, Rose J, et al. The extra domain A of fibronectin activates Toll-like receptor 4. J Biol Chem 2001; 276: 1022933.
  • 26
    Termeer C, Benedix F, Sleeman J, Fieber C, Voith U, Ahrens T, et al. Oligosaccharides of hyaluronan activate dendritic cells via Toll-like receptor 4. J Exp Med 2002; 195: 99111.
  • 27
    Koski GK, Kariko K, Xu S, Weissman D, Cohen PA, Czerniecki BJ. Cutting edge: innate immune system discriminates between RNA containing bacterial versus eukaryotic structural features that prime for high-level IL-12 secretion by dendritic cells. J Immunol 2004; 172: 398993.
  • 28
    Gallucci S, Lolkema M, Matzinger P. Natural adjuvants: endogenous activators of dendritic cells. Nat Med 1999; 5: 124955.
  • 29
    Johnson GB, Brunn GJ, Kodaira Y, Platt JL. Receptor-mediated monitoring of tissue well-being via detection of soluble heparan sulfate by Toll-like receptor 4. J Immunol 2002; 168: 52339.
  • 30
    Ichikawa HT, Williams LP, Segal BM. Activation of APCs through CD40 or Toll-like receptor 9 overcomes tolerance and precipitates autoimmune disease. J Immunol 2002; 169: 27817.
  • 31
    Waldner H, Collins M, Kuchroo VK. Activation of antigen-presenting cells by microbial products breaks self tolerance and induces autoimmune disease. J Clin Invest 2004; 113: 9907.
  • 32
    Martin CA, Carsons SE, Kowalewski R, Bernstein D, Valentino M, Santiago-Schwarz F. Aberrant extracellular and dendritic cell (DC) surface expression of heat shock protein (hsp)70 in the rheumatoid joint: possible mechanisms of hsp/DC-mediated cross-priming. J Immunol 2003; 171: 573642.
  • 33
    Radstake TR, Roelofs MF, Jenniskens YM, Oppers-Walgreen B, van Riel PL, Barrera P, et al. Expression of Toll-like receptors 2 and 4 in rheumatoid synovial tissue and regulation by proinflammatory cytokines interleukin-12 and interleukin-18 via interferon-γ. Arthritis Rheum 2004; 50: 385665.
  • 34
    Seibl R, Birchler T, Loeliger S, Hossle JP, Gay RE, Saurenmann T, et al. Expression and regulation of Toll-like receptor 2 in rheumatoid arthritis synovium. Am J Pathol 2003; 162: 12217.
  • 35
    Radstake TR, Franke B, Hanssen S, Netea MG, Welsing P, Barrera P, et al. The Toll-like receptor 4 Asp299Gly functional variant is associated with decreased rheumatoid arthritis disease susceptibility but does not influence disease severity and/or outcome. Arthritis Rheum 2004; 50: 9991001.
  • 36
    Leadbetter EA, Rifkin IR, Hohlbaum AM, Beaudette BC, Shlomchik MJ, Marshak-Rothstein A. Chromatin-IgG complexes activate B cells by dual engagement of IgM and Toll-like receptors. Nature 2002; 416: 6037.
  • 37
    Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS, et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988; 31: 31524.
  • 38
    Lien E, Means TK, Heine H, Yoshimura A, Kusumoto S, Fukase K, et al. Toll-like receptor 4 imparts ligand-specific recognition of bacterial lipopolysaccharide. J Clin Invest 2000; 105: 497504.
  • 39
    De Jager W, te Velthuis H, Prakken BJ, Kuis W, Rijkers GT. Simultaneous detection of 15 human cytokines in a single sample of stimulated peripheral blood mononuclear cells. Clin Diagn Lab Immunol 2003; 10: 1339.
  • 40
    Mullarkey M, Rose JR, Bristol J, Kawata T, Kimura A, Kobayashi S, et al. Inhibition of endotoxin response by e5564, a novel Toll-like receptor 4-directed endotoxin antagonist. J Pharmacol Exp Ther 2003; 304: 1093102.
  • 41
    Van der Heijde DM, van 't Hof MA, van Riel PL, Theunisse LM, Lubberts EW, van Leeuwen MA, et al. Judging disease activity in clinical practice in rheumatoid arthritis: first step in the development of a disease activity score. Ann Rheum Dis 1990; 49: 91620.
  • 42
    Edinger JW, Bonneville M, Scotet E, Houssaint E, Schumacher HR, Posnett DN. EBV gene expression not altered in rheumatoid synovia despite the presence of EBV antigen-specific T cell clones. J Immunol 1999; 162: 3694701.
  • 43
    Hamerman D, Gresser I, Smith C. Isolation of cytomegalovirus from synovial cells of a patient with rheumatoid arthritis. J Rheumatol 1982; 9: 65864.
  • 44
    Saal JG, Steidle M, Einsele H, Muller CA, Fritz P, Zacher J. Persistence of B19 parvovirus in synovial membranes of patients with rheumatoid arthritis. Rheumatol Int 1992; 12: 14751.
  • 45
    Stierle G, Brown KA, Rainsford SG, Smith CA, Hamerman D, Stierle HE, et al. Parvovirus associated antigen in the synovial membrane of patients with rheumatoid arthritis. Ann Rheum Dis 1987; 46: 21923.
  • 46
    Fujita M, Into T, Yasuda M, Okusawa T, Hamahira S, Kuroki Y, et al. Involvement of leucine residues at positions 107, 112, and 115 in a leucine-rich repeat motif of human Toll-like receptor 2 in the recognition of diacylated lipoproteins and lipopeptides and staphylococcus aureus peptidoglycans. J Immunol 2003; 171: 367583.
  • 47
    Siedlar M, Frankenberger M, Benkhart E, Espevik T, Quirling M, Brand K, et al. Tolerance induced by the lipopeptide Pam3Cys is due to ablation of IL-1R-associated kinase-1. J Immunol 2004; 173: 273645.
  • 48
    Horng T, Barton GM, Flavell RA, Medzhitov R. The adaptor molecule TIRAP provides signalling specificity for Toll-like receptors. Nature 2002; 420: 32933.
  • 49
    Wald D, Qin J, Zhao Z, Qian Y, Naramura M, Tian L, et al. SIGIRR, a negative regulator of Toll-like receptor–interleukin 1 receptor signaling. Nat Immunol 2003; 4: 9207.